193290-80-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-formylbenzoic acid is used as a key building block for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs with improved therapeutic properties. 3-Fluoro-4-formylbenzoic acid's ability to form new chemical bonds allows for the creation of diverse drug candidates with potential applications in treating a wide range of diseases and conditions.
Used in Agrochemical Industry:
3-Fluoro-4-formylbenzoic acid is also employed as a starting material in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and structural features enable the development of novel agrochemicals with enhanced efficacy and selectivity, contributing to more effective crop protection and management strategies.
Used in Organic Synthesis:
As a versatile chemical intermediate, 3-Fluoro-4-formylbenzoic acid is widely used in organic synthesis for the preparation of various organic compounds. Its reactivity and the presence of the formyl and carboxylic acid groups make it a valuable precursor for the synthesis of complex organic molecules, including natural products, fine chemicals, and specialty chemicals.
Used in Research and Development:
3-Fluoro-4-formylbenzoic acid serves as an important research tool in the field of organic chemistry. Its unique structure and reactivity make it an attractive candidate for studying various chemical reactions and mechanisms. Researchers can use 3-Fluoro-4-formylbenzoic acid to explore new synthetic routes, develop innovative methodologies, and gain insights into the fundamental aspects of organic chemistry.

Upstream product

• 74733-25-8 methyl 3-fluoro-4-formylbenzoate 
• 350-28-7 3-fluoro-4-methyl-benzoic acid 
• 777074-51-8 4-(dibromomethyl)-3-fluorobenzoic acid 

Downstream Products

• 74733-25-8 methyl 3-fluoro-4-formylbenzoate 
• 1134776-60-5 4-(2,5-cis/trans-dimethylpyrrolidine-1-carbonyl)-2-fluorobenzaldehyde 
• 777074-52-9 benzyl 3-fluoro-4-formylbenzoate 
• 314241-04-8 2-fluoro-terephthalic acid 4-methyl ester 

Relevant academic research and scientific papers

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.

Efficient three-component synthesis of diversely substituted tetrahydro-1H-cyclopenta[c]quinolines

The synthesis of highly functionalized substituted tetrahydro-1H-cyclopenta[c]quinoline (I) and its reduced derivatives hexahydro-1H-cyclopenta[c]quinolines (II) via Povarov reaction in high diastereoselectivity and high to moderate yields is described he

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

New CRTH2 Antagonists

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

Modeling, synthesis and biological evaluation of potential Retinoid X Receptor (RXR) selective agonists: Novel analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene)

This report describes the synthesis of analogues of 4-[1-(3,5,5,8,8- pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), commonly known as bexarotene, and their analysis in acting as retinoid X receptor (RXR)-specific agonists. Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can cause side effects such as hypothyroidism and increased triglyceride concentrations, presumably by disruption of RXR heterodimerization with other nuclear receptors. The novel analogues in the present study have been evaluated forRXR activation in an RXR mammalian-2-hybrid assay as well as an RXRE-mediated transcriptional assay and for their ability to induce apoptosis as well as for their mutagenicity and cytotoxicity. Analysis of 11 novel compounds revealed the discovery of three analogues that best induce RXR-mediated transcriptional activity, stimulate apoptosis, have comparable Ki and EC50 values to 1, and are selective RXR agonists. Our experimental approach suggests that rational drug design can develop new rexinoids with improved biological properties. 2009 American Chemical Society.

SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS

Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.

PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disease, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Synthesis and structure-activity relationship of novel RXR antagonists: Orally active anti-diabetic and anti-obesity agents

A series of diazepinylbenzoic acid derivatives were synthesized and tested in the inhibition assay of the transactivation of RXR. Oral treatment of cyano derivatives (16f) was found to show anti-diabetic and anti-obesity effects in KK-Ay mice.

11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS

The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, for delaying progression of, preventing or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, comp